Atoltivimab

Atoltivimab (REGN3470), or maftivimab/odesivimab (Inmazeb) is the first Food and agent Administration (FDA) -approved monoclonal antibody to target Zaire ebolavirus (EBOVs) infection[1].

Product Specifications

CAS Number

[2135632-29-8]

Product Name Alternative

REGN3470

UNSPSC

12352203

Target

Filovirus

Type

Inhibitory Antibodies

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/atoltivimab.html

Purity

98.66

Solubility

10 mM in DMSO

Smiles

[Atoltivimab]

Molecular Weight

(145.1 kDa)

References & Citations

[1]Saxena D, et al. Atoltivimab/maftivimab/odesivimab (Inmazeb) combination to treat infection caused by Zaire ebolavirus. Drugs Today (Barc) . 2021 Aug;57 (8) :483-490.